Association Between Phosphate Disturbances and Mortality Among Critically Ill Patients With Sepsis or Septic Shock

Shmeylan Al Harbi  
King Saud bin Abdulaziz University for Health Sciences

Hasan Al-Dorzi  
King Saud bin Abdulaziz University for Health Sciences

Albatool Al Meshari  
Saudi Food and Drug Authority

Hani Tamim  
King Saud bin Abdulaziz University for Health Sciences

Sheryl Ann Abdukahil  
King Saud bin Abdulaziz University for Health Sciences

Musharaf Sadat  
King Saud bin Abdulaziz University for Health Sciences

Yaseen Arabi (✉️ yaseenarabi@yahoo.com)  
King Saud bin Abdulaziz University for Health Sciences

Research Article

**Keywords:** Phosphate, Mortality, Sepsis, Septic shock, Critically Ill, Intensive care, Saudi Arabia

**DOI:** https://doi.org/10.21203/rs.3.rs-149787/v1

**License:** ☐  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Objective: The aim of this study is to examine the association of hypophosphatemia and hyperphosphatemia on the first day of ICU admission with mortality in septic critically ill patients.

Methods: In this retrospective cohort study, all adult patients who were admitted to medical-surgical ICUs between 2014 and 2017 with sepsis or septic shock were categorized as having hypophosphatemia, hyperphosphatemia or based on day 1 serum phosphate values. We compared the clinical characteristics and outcomes between the three groups. We used multivariate analysis to examine the association of hypophosphatemia and hyperphosphatemia with these outcomes.

Results: Of the 1422 patients enrolled in the study, 188 (13%) had hypophosphatemia, 865 (61%) normophosphatemia and 369 (26%) had hyperphosphatemia. Among the three groups, the patients in the hyperphosphatemia group had significantly lower GCS, higher APACHE II scores, higher serum creatinine, increased use of vasopressors, and required mechanical ventilation with lower PaO2/FiO2 ratio compared with the other two groups. In addition, hyperphosphatemia group also showed significantly higher ICU mortality and hospital mortality in comparison to the other two groups.

Conclusion: Hyperphosphatemia and not hypophosphatemia on the first ICU admission day was associated with an increase in the ICU and hospital mortality in septic critically ill patients.

Background

Acute critical illness predisposes patients to serum phosphate disturbances \(^1\text{-}\text{6}\), whether hypo or hyperphosphatemia. In these patients, hypophosphatemia may develop as a result of decreased intake or absorption, increase renal execration, and/ or internal redistribution. It can be seen in patients with hyperventilation, respiratory alkalosis, insulin secretion and provision, hungry bone syndrome and refeeding syndrome \(^7\). On the other hand, hyperphosphatemia occurs as a consequence of renal dysfunction, iatrogenic administration of large phosphate load, tumor lysis syndrome, hemolysis, rhabdomyolysis or lactic ketoacidosis \(^8\).

The reported prevalence of hypophosphatemia in critically ill patients varied widely across different studies and ranges between 10\% and 80\% \(^9\text{-}\text{11}\). It is particularly high in sepsis. Hypophosphatemia is considered one of the early findings of sepsis. Studies have shown that hypophosphatemia occurs in up to 80\% of septic patients and is associated with very high levels of tumor necrosis factor-alpha and interleukin (IL)-6 and of soluble IL receptor-2R and IL-6R, especially in those patients with positive blood cultures \(^10\text{,}\text{12}\). Hyperphosphatemia is also common in the intensive care unit (ICU). In a study of 2,700 of ICU patients, 45\% of more than 10,000 serum phosphate measurements were indicative of hyperphosphatemia \(^7\). Another study found that hyperphosphatemia was independently associated with 28-day in-hospital mortality \(^13\). Sepsis, which is commonly associated with acute kidney injury, is also a risk factor for hyperphosphatemia.
Serum phosphate disturbances have been associated with adverse clinical outcomes, such as the need for prolonged mechanical ventilation, cardiac dysfunction and arrhythmias, hematologic dysfunction, and insulin resistance. The evidence on the clinical significance of serum phosphate disturbances in patients with sepsis remains scarce and controversial. It is unclear if phosphate disturbances are independently associated with mortality in septic patients or they represent markers for higher severity of illness. Thus, we sought to examine the association of hypophosphatemia and hyperphosphatemia with mortality among septic patients.

**Methods**

**Setting**

This is a retrospective cohort study that was conducted in the adult medical-surgical ICU of King Abdulaziz Medical City, which is a tertiary-care academic referral hospital in Riyadh, Saudi Arabia. The ICU admits medical and surgical patients, and operates as a closed unit with onsite coverage by critical care board-certified intensivists 24 hours per day, 7 days per week. The nurse-to-patient ratio in the unit is approximately 1:1.2. In addition, clinical pharmacists are a part of the daily multidisciplinary rounds. The ICU has an electrolyte replacement protocol for hypokalemia, hypophosphatemia and hypomagnesemia. The dose of replaced electrolyte depends on the respective serum level taking into consideration kidney function and weight.

This study was approved by the Institutional Review Board of the Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

**Participants**

All adult patients who were admitted to the medical-surgical ICU between January 2014 and September 2017 were screened for the following inclusion criteria: age ≥ 18 years old, sepsis or septic shock on ICU admission, and expected ICU length of stay (LOS) > 24 hours. Sepsis was defined as a life-threatening organ dysfunction caused by an infection that dysregulated host response to an infection. If there was persistent hypotension that required vaspressors, then the patient was classified as having septic shock. Exclusion criteria included admission to the Burn Unit, pregnancy or receiving parenteral nutrition, vitamin D preparations, or phosphate binders. Cardiac patients, including those admitted with ST-elevation myocardial infarction were admitted to cardiac ICUs and hence were not included in this study.

**Data collection**

The following data were extracted from hospital information system BESTCare (BESTCare 2.0, Seoul, South Korea) and the ICU database: age, gender, admission category (medical, surgical, and non-operative trauma or non-operative and post-operative), Acute Physiology and Chronic Health Evaluation (APACHE II) score, Glasgow Coma Scale (GCS), chronic comorbidities (chronic liver disease, chronic cardiovascular disease,
chronic respiratory disease, chronic renal disease and chronic immunosuppression) as defined by the APACHE system, history of diabetes mellitus, presence of sepsis or sepsis shock on admission, presence of acute kidney injury, need for mechanical ventilation and vasopressor use. We also documented the admission serum creatinine level, International Normalized Ratio (INR) and platelet count.

The patients in this study were divided into three groups based on their serum phosphate level during the first 24 hours of ICU admission. The normophosphatemia group was defined as a patient with phosphate level of 0.74 to 1.52 mmol/L, while hypophosphatemia less than 0.73 mmol/L, and hyperphosphatemia more than 1.52 mmol/L. These cutoffs were selected based on the thresholds for phosphate replacement in the ICU electrolyte replacement protocol and the hospital laboratory reference values.

Outcomes

The primary outcomes were ICU and hospital mortality. The secondary outcomes were mechanical ventilation duration and ICU and hospital length of stay.

Statistical analysis

Statistical analysis was performed using the Statistical Analysis Software (SAS, Release 8, SAS Institute Inc., Cary, NC, 1999, USA). Baseline characteristics, interventions and outcomes were reported as numbers with percentages for categorical variables and as medians with the first and third quartiles (Q1 and Q3, respectively) for continuous variables. They were compared among groups using the Chi-square test and ANOVA, respectively.

To determine if phosphate level was an independent predictor for hospital mortality, multivariable logistic regression analysis was performed with the normophosphatemia group as the reference. The variables included in the model were those known to be clinically relevant (age, APACHE II, sex, serum creatinine). Results were presented as adjusted odds ratio (aOR) with 95% confidence interval (CI).

We carried out subgroup analyses with stratification by the following variables: age, sepsis, diabetes, vasopressor use, operative admission category, chronic cardiac, respiratory and liver disease, chronic immunosuppression, acute kidney injury, and hypertension, adjusting for the same clinically relevant covariates mentioned above. Tests of interaction were performed to assess whether these variables were effect modifiers of the association between phosphate level and mortality. A p-value ≤ 0.05 was considered statistically significant.

Results

Patient characteristics

Of the 1422 patients enrolled in the study, 188 (13%) were categorized as hypophosphatemia with a median of 0.6 mmol/L, 369 (26%) as hyperphosphatemia with a median of 1.9 mmol/L, and 865 (61%) as
normophosphatemia with a median of 1.09 mmol/L at day one of their ICU admission. Table 1 presents the baseline characteristics of the hypophosphatemia, normophosphatemia and hyperphosphatemia groups.

Among the three groups, patients who had hyperphosphatemia had significantly lower GCS (13 (8, 15)), higher APACHE II scores (26 (21, 30)), higher serum creatinine (188 (111,302) mmol/L), higher use of vasopressors (65.6%), and required more mechanical ventilation (63.1%) with lower PaO2/FiO2 ratio 171 (108, 361; p-value <0.0001). Also chronic cardiac and renal disease were significantly more prevalent in the hyperphosphatemia group (p <0.0001). Moreover, the hyperphosphatemia group had significant coagulopathy with lower platelet count than the other two groups (p <0.0001).

**Outcomes**

Table 2 presents the outcomes of the three patient groups. The hyperphosphatemia group showed significantly higher ICU mortality (114 (32.0%)) and hospital mortality (165 (44.7%)) when compared with hypophosphatemia and normophosphatemia group (p <0.0001). The median hospital length of stay was higher in the hypophosphatemia group (22 days; Q1, Q3: 7, 51) and normophosphatemia group (22 days; Q1, Q3: 12,51) than those with hyperphosphatemia (17 days; Q1, Q3: 7, 39). In contrast, mechanical ventilation duration was longer in the hyperphosphatemia group (2 days; Q1, Q3: 0, 6 versus 0; Q1, Q3: 0, 4 for hypophosphatemia patients). However, among survivors only, there was no difference in the ICU length of stay, hospital length of stay and ventilation duration between the three groups.

On multivariate logistic regression analysis, hyperphosphatemia was found to be significantly associated with ICU mortality (aOR 1.6, 95% CI 1.13-2.28, p=0.008) and hospital mortality (aOR 1.7, 95% CI 1.21-2.29, p=0.002, respectively) when compared to normophosphatemia group. However, there was no association between ICU and hospital mortality with hypophosphatemia and normophosphatemia patients (ICU mortality: aOR 0.60, 95 % CI: 0.33-1.1, p=0. 08; hospital mortality: aOR 0.89, 95 % CI:0.57-1.38, p=0.59).

Table 3.

Tables 4 and 5 show the association between phosphate levels and all-cause ICU or hospital mortality in several subgroups of patients. The multivariant analysis showed that among non-liver disease hyperphosphatemia patients were associated with higher ICU mortality (aOR=1.68, 95% CI 1.61-2.42), p=0.007) compared with normophosphatemia group.

Furthermore, there were no significant differences in-hospital mortality in the selected subgroups patients as shown in Table 5.

**Discussion**

Our study showed that hyperphosphatemia, but not hypophosphatemia, during the first 24 hours of ICU admission was associated with an increase in-hospital mortality in critically ill patients with sepsis or septic shock.
Phosphate has various physiological functions. It is a vital component for intracellular metabolism and affects respiratory muscle contractility, neuronal transmission, and electrolyte transport. Furthermore, it has a role in supplying oxygen to tissues, maintaining plasma and urinary pH, coagulation cascade as well as body immune system \(^1\), \(^6\), \(^24\).

Studies that evaluated the association between hypophosphatemia and mortality had controversial results \(^1\). This is could be due to several limitations of the other studies, low sample size, variety of settings, targeting different patients, and uneven cut points of phosphate concentration levels between the studies. Shore et al. conducted a retrospective study that compared severe hypophosphatemia (phosphate level <1 mg/dl) versus hypophosphatemia (phosphate level >1 mg/dl) and mortality in 55 patients with sepsis. They found that those with severe hypophosphatemia had significantly higher mortality rates (80.8% versus 34.5%; \(p=0.001\)) \(^25\). Sankaran et al. conducted a retrospective study that reviewed the laboratory abnormalities of 302 patients who were admitted to ICU with bacterial pneumonia. They showed that hypophosphatemic patients experienced a higher mortality compared to normophosphatemic subjects (\(p<0.001\)) \(^26\). Zazzo JF et al. evaluated 208 patients who were admitted to the surgical ICU over 6 months and found the mortality was higher in the hypophosphatemic group than in the normophosphatemic group (30% versus 15.2%; \(p<0.05\)) \(^27\). In contrast, many other studies did not find any association between hypophosphatemia and mortality. Demirjian et al. reported a single-center prospective observational study in which 321 patients with acute kidney injury on continuous renal replacement therapy were included for the association of mortality. Hypophosphatemia occurred more frequent during dialysis but was not significantly associated with 28-day mortality (OR 1.16; 95% CI 0.76-1.77) \(^17\). Lim C et al. analyzed data from a prospective cohort study of medical and surgical ICU patients with renal replacement therapy for acute kidney injury and found no significant difference in both ICU mortality and hospital mortality in patients with hypophosphatemia compared without hypophosphatemia \(^29\) Yang Y et al. retrospectively investigated hypophosphatemia in critically ill patients with acute kidney injury who received continuous venovenous hemofiltration, and also showed hypophosphatemia was not associated with 28-day ICU mortality (\(p=0.7\)) \(^30\). Suzuki et al. conducted a retrospective observational study that included generally critically ill patients and showed that hypophosphatemia was not associated with ICU mortality (aOR 0.86, 95% CI, 0.66-1.10; \(p=0.24\)) and hospital mortality (OR 0.89, 0.73-1.07; \(p=0.21\)) on multivariable logistic regression analysis. They concluded that hypophosphatemia was likely a marker of illness severity \([13]\).

Haider et al. had supported this finding as well as they showed no association between hypophosphatemia and mortality in general critically ill patients who presented to the emergency room \(^13\).

Few studies looked at the association between hyperphosphatemia and mortality. Indeed, their findings were consistent with our findings. Haider et al. studied the association between hospital mortality and phosphate level in unselected patients presenting at an emergency room. Their results showed that hyperphosphatemia was associated with a significant increase in-hospital mortality (OR 3.29, 95% CI 1.8-6.1, \(p<0.001\)) \(^13\). In a post hoc analysis, Kuo et al. evaluated data of patients who were admitted to a burn unit and found that the 90-day mortality was higher in the hyperphosphatemia group (53.8% vs 18.1%, \(p<0.001\)), and the difference was still significant even when adjusting for several confounding factors (hazard ratio 2.05, 95% CI, 1.17-3.59) \(^25\). Miller et al. evaluated 197 ICU patients who were hospitalized for
severe sepsis or septic shock and on mechanical ventilation and found that 33 (16.7%) of them were hypophosphatemic, and 41 (20.8%) hyperphosphatemic. The mortality rate was significantly higher among those with hyperphosphatemia (p=0.012)\textsuperscript{26}.

Our study has both strengths and limitations. The strengths are, first, the inclusion of a larger sample size from different medical, surgical, trauma and neurocritical ICUs; and second, comparing 3 groups of phosphate concentration levels on the first day of ICU admission to avoid possible confounder factors such as therapeutic interventions of nutrition, phosphate binders, insulin, and catecholamines. On the other hand, the limitations of our study include its retrospective design and that data were collected in a single tertiary medical center which may limit the generalization of our findings.

**Conclusion**

In patients with severe sepsis and septic shock, hyperphosphatemia was associated with increased hospital mortality. Further studies are needed to clarify the impact of hypophosphatemia as well as hyperphosphatemia in critically ill populations.

**Abbreviations**

ICU: Intensive care unit

APACHE: Acute Physiology and Chronic Health Evaluation

GCS: Glasgow Coma Scale

eGFR: Estimated glomerular filtration rate

INR: International Normalized Ratio

aOR: Adjusted odds ratio

CI: Confidence interval

**Declarations**

**Ethics approval**

This study was approved by the King Abdullah International Medical Research Center (KAIMRC)-Ministry of National Guard Health Affairs- Institutional Review Board and all methods were performed in accordance with the relevant guidelines and regulations.

**Consent to participate**

The informed consent for the present analysis was waived because of the observational nature of the study by King Abdullah International Medical Research Center (KAIMRC)-Ministry of National Guard Health
Affairs- Institutional Review Board.

Consent to publish
Not applicable

Competing interests
The authors have no financial or non-financial competing interests to declare.

Funding
None

Authors' Contributions

SAA: Conception and design, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, supervision and final approval of the version to be published.

HMD: Analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content and final approval of the version to be published.

AMA: Data collection, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content and final approval of the version to be published.

HMT: Analysis and interpretation of data, critical revision of the manuscript for important intellectual content and final approval of the version to be published.

SIA: Analysis and tabulation of data, and final approval of the version to be published.

MS: Acquisition of data, critical revision of the manuscript for important intellectual content, and final approval of the version to be published.

YMA: Acquisition of data, conception and design, analysis and interpretation of data, statistical analysis, critical revision of the manuscript and overall supervision

Acknowledgments
None

References

1. Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010; 14: R147. DOI: 10.1186/cc9215.
2. Cohen J, Kogan A, Sahar G, et al. Hypophosphatemia following open heart surgery: incidence and consequences. *Eur J Cardiothorac Surg* 2004; 26: 306-310. DOI: 10.1016/j.ejcts.2004.03.004.

3. Salem RR and Tray K. Hepatic resection-related hypophosphatemia is of renal origin as manifested by isolated hyperphosphaturia. *Annals of surgery* 2005; 241: 343-348. 2005/01/15.

4. Daily WH, Tonnesen AS and Allen SJ. Hypophosphatemia—incidence, etiology, and prevention in the trauma patient. *Crit Care Med* 1990; 18: 1210-1214.

5. Berger MM, Rothen C, Cavadini C, et al. Exudative mineral losses after serious burns: a clue to the alterations of magnesium and phosphate metabolism. *Am J Clin Nutr* 1997; 65: 1473-1481. DOI: 10.1093/ajcn/65.5.1473.

6. Lee JW. Fluid and electrolyte disturbances in critically ill patients. *Electrolyte Blood Press* 2010; 8: 72-81. DOI: 10.5049/EBP.2010.8.2.72.

7. Mehanna HM, Moledina J and Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. *BMJ (Clinical research ed)* 2008; 336: 1495-1498. 2008/06/28. DOI: 10.1136/bmj.a301.

8. O’Connor LR, Klein KL and Bethune JE. Hyperphosphatemia in lactic acidosis. *N Engl J Med* 1977; 297: 707-709. DOI: 10.1056/NEJM197709292971307.

9. Bech A, Blans M, Raaijmakers M, et al. Hypophosphatemia on the intensive care unit: individualized phosphate replacement based on serum levels and distribution volume. *J Crit Care* 2013; 28: 838-843. DOI: 10.1016/j.jcrc.2013.03.002.

10. Barak V, Schwartz A, Kalickman I, et al. Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines. *Am J Med* 1998; 104: 40-47.

11. Suzuki S, Egi M, Schneider AG, et al. Hypophosphatemia in critically ill patients. *J Crit Care* 2013; 28: e539-519. DOI: 10.1016/j.jcrc.2012.10.011.

12. Brotfain E, Schwartz A, Boniel A, et al. Clinical outcome of critically ill patients with thrombocytopenia and hypophosphatemia in the early stage of sepsis. *Anaesthesiol Intensive Ther* 2016; 48: 294-299. DOI: 10.5603/AIT.a2016.0053.

13. Haider DG, Lindner G, Wolzt M, et al. Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study. *PloS one* 2015; 10: e0133426. 2015/08/08. DOI: 10.1371/journal.pone.0133426.

14. Zhao Y, Li Z, Shi Y, et al. Effect of hypophosphatemia on the withdrawal of mechanical ventilation in patients with acute exacerbations of chronic obstructive pulmonary disease. *Biomed Rep* 2016; 4: 413-416. DOI: 10.3892/br.2016.605.

15. Alsumrain MH, Jawad SA, Imran NB, et al. Association of hypophosphatemia with failure-to-wean from mechanical ventilation. *Ann Clin Lab Sci* 2010; 40: 144-148.

16. Talakoub R, Bahrami M, Honarmand A, et al. The Predicting Ability of Serum Phosphorus to Assess the Duration of Mechanical Ventilation in Critically Ill Patients. *Adv Biomed Res* 2017; 6: 51. DOI: 10.4103/2277-9175.205192.

17. Demirjian S, Teo BW, Guzman JA, et al. Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. *Nephrology, dialysis,
18. Ognibene A, Ciniglio R, Greifenstein A, et al. Ventricular tachycardia in acute myocardial infarction: the role of hypophosphatemia. *South Med J* 1994; 87: 65-69.

19. Arabi Y, Alshimemeri A and Taher S. Weekend and weeknight admissions have the same outcome of weekday admissions to an intensive care unit with onsite intensivist coverage. *Crit Care Med* 2006; 34: 605-611. 2006/03/08.

20. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; 13: 818-829. 1985/10/01.

21. Livingston BM, Mackenzie SJ, MacKirdy FN, et al. Should the pre-sedation Glasgow Coma Scale value be used when calculating Acute Physiology and Chronic Health Evaluation scores for sedated patients? Scottish Intensive Care Society Audit Group. *Crit Care Med* 2000; 28: 389-394. 2000/03/09.

22. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; 315: 801-810. DOI: 10.1001/jama.2016.0287.

23. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11: R31. DOI: 10.1186/cc5713.

24. Kuo G, Lee C-C, Yang S-Y, et al. Hyperphosphatemia is associated with high mortality in severe burns. *PloS one* 2018; 13: e0190978-e0190978. DOI: 10.1371/journal.pone.0190978.

25. Shor R, Halabe A, Rishver S, et al. Severe hypophosphatemia in sepsis as a mortality predictor. *Ann Clin Lab Sci* 2006; 36: 67-72. 2006/02/28.

26. Zazzo JF, Troche G, Ruel P, et al. High incidence of hypophosphatemia in surgical intensive care patients: efficacy of phosphorus therapy on myocardial function. *Intensive care medicine* 1995; 21: 826-831. 1995/10/01.

27. Lim C, Tan HK and Kaushik M. Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events. *Clinical kidney journal* 2017; 10: 341-347. 2017/06/16. DOI: 10.1093/ckj/sfw120.

**Tables**

**Table 1:** Baseline and clinical characteristics of patients with hypophosphatemia (Phosphate<0.74 mmol/L), normophosphatemia (Phosphate-0.74-1.52 mmol/L) and hyperphosphatemia (Phosphate>1.52 mmol/L)
| Variable                        | Hypophosphatemia group N= 188 | Normophosphatemia group N= 865 | Hyperphosphatemia group N= 369 | p value |
|--------------------------------|--------------------------------|--------------------------------|--------------------------------|---------|
| Age (years), median (Q1, Q3)   | 62 (42,75)                     | 67 (50,76)                     | 66 (56,75)                     | 0.09    |
| Female sex, n (%)              | 87 (46.3)                      | 353 (40.8)                     | 156 (42.3)                     | 0.38    |
| Admission category, n (%)      |                                |                                |                                |         |
| Medical                        | 185 (98.4)                     | 849 (98.2)                     | 362 (98.1)                     | 0.94    |
| Surgical                       | 3 (1.6)                        | 15 (1.7)                       | 6 (1.6)                        |         |
| Non-operative trauma           | 0 (0)                          | 1 (0.12)                       | 1 (0.3)                        |         |
| APACHE II, median (Q1, Q3)     | 19 (15,24)                     | 21 (16,26)                     | 26 (21,30)                     | <0.0001 |
| Mechanical ventilation, n (%)  | 83 (44.2)                      | 411 (47.5)                     | 233 (63.1)                     | <0.0001 |
| GCS, median (Q1, Q3)           | 14 (10,15)                     | 14 (10,15)                     | 13 (8,15)                      | 0.006   |
| Vasopressor, n (%)             | 84 (44.7)                      | 406 (46.9)                     | 242 (65.6)                     | <0.0001 |
| PaO₂/FiO₂ ratio, median (Q1, Q3)| 216 (132,316)                  | 216 (132,316)                  | 171 (108,361)                  | <0.0001 |
| Chronic comorbidities- n (%)   |                                |                                |                                |         |
| Chronic respiratory disease, n (%)| 7 (3.7)                      | 56 (6.5)                       | 17 (4.6)                       | 0.20    |
| Chronic cardiac disease, n (%) | 30 (15.9)                      | 252 (29.13)                    | 133 (36.0)                     | <0.0001 |
| Chronic liver disease, n (%)   | 14 (7.5)                       | 48 (5.6)                       | 36 (9.8)                       | 0.03    |
| Chronic immunosuppression, n (%)| 43 (22.9)                      | 177 (20.5)                     | 58 (15.7)                      | 0.07    |
| Chronic renal disease, n (%)   | 4 (2.1)                        | 19 (2.2)                       | 25 (6.8)                       | 0.0001  |
| Acute Kidney Injury, n (%)     | 14 (7.5)                       | 144 (16.7)                     | 132 (35.8)                     | <0.0001 |
### Table 2: Outcomes of patients with hypophosphatemia, normophosphatemia and hyperphosphatemia.

|                              | Hypophosphatemia | Normophosphatemia | Hyperphosphatemia | P-value  |
|------------------------------|------------------|-------------------|-------------------|----------|
| **Creatinine (mmol/L), median (Q1, Q3)** | 67 (50.98)       | 90 (60.154)       | 188 (111,302)     | <0.0001  |
| **INR, median (Q1, Q3)**     | 1.3 (1.1,1.6)    | 1.3 (1.1,1.6)     | 1.5 (1.2,2)       | <0.0001  |
| **Platelet (10⁹/L), median (Q1, Q3)** | 164 (89,255)    | 203 (119.5,308)   | 164 (90,289)      | <0.0001  |
| **Average phosphate level (mmol/L), median (Q1, Q3)** | 0.6 (0.5,0.7)   | 1.09 (0.9,1.3)    | 1.9 (1.7,2.2)     | <0.0001  |
| **Lactic acid (mmol/L), median (Q1,Q3)** | 2.2 (1.3,4.3)   | 1.9 (1.2,3.3)     | 3.09 (1.5,6.9)    | <0.0001  |
| **Estimated GFR, median (Q1, Q3)** | 93.6 (58.5,139.5)| 70.4 (37.2,117.1) | 27.6 (17.6,54.1)  | <0.0001  |

**APACHE**: Acute Physiology and Chronic Health Evaluation, **GCS**: Glasgow Coma Scale, **INR**: International Normalized Ratio, **Q1**: the first quartile, **Q3**: the third quartile
| Variable                                      | Hypophosphatemia group | Normophosphatemia group | Hyperphosphatemia group | p-value |
|----------------------------------------------|------------------------|-------------------------|-------------------------|---------|
| Categorical outcomes                         |                        |                         |                         |         |
| ICU mortality, n (%)                         | 21 (11.4)              | 143 (17.1)              | 114 (32.0)              | <0.0001 |
| Hospital mortality, n (%)                   | 44 (23.5)              | 226 (26.2)              | 165 (44.7)              | <0.0001 |
| Continuous outcomes in all patients          |                        |                         |                         |         |
| ICU length of stay (days), median (Q1, Q3)   | 3.1 (0.83, 9.3)        | 3.9 (1.04, 10.04)       | 2.8 (0.7, 10)           | 0.09    |
| Hospital length of stay (days), median (Q1, Q3) | 22 (7,51)              | 22 (12,51)              | 17 (7,39)               | 0.001   |
| Mechanical ventilation duration (days), median (Q1, Q3) | 0 (0,4)               | 1 (0,6)                 | 2 (0,6)                 | 0.005   |
| Continuous outcomes in survivors             |                        |                         |                         |         |
| ICU length of stay (days), median (Q1, Q3)   | 2.8 (0.7, 8.5)         | 3.3 (0.9, 9.1)          | 2.7 (0.4, 9.9)          | 0.42    |
| Hospital length of stay (days), median (Q1, Q3) | 22 (10, 53)            | 22 (12, 52)             | 26.5 (14.5, 65)         | 0.46    |
| Mechanical ventilation duration (days), median (Q1, Q3) | 0 (0, 4)              | 0 (0, 3)                | 1 (0, 4)                | 0.21    |

ICU: intensive care unit, Q1: the first quartile, Q3: the third quartile

**Table 3:** Multivariate logistic regression analysis of the association of phosphate levels and mortality.
|                          | Hypophosphatemia group vs Normophosphatemia group | Hyperphosphatemia group vs Normophosphatemia group |
|--------------------------|--------------------------------------------------|---------------------------------------------------|
| **aOR**                  | 0.60                                             | 1.6                                               |
| **95% CI**               | 0.33-1.1                                         | 1.13-2.28                                         |
| **p-value**              | 0.08                                             | 0.008                                             |
| **ICU mortality**        |                                                  |                                                   |
| **Hospital mortality**   | 0.89                                             | 1.7                                               |
| **95% CI**               | 0.57-1.38                                        | 1.21-2.29                                         |
| **p-value**              | 0.59                                             | 0.002                                             |

aOR: adjusted odds ratio, CI: confidence interval

**Table 4**: Multivariate analysis of the association of phosphate levels and ICU mortality in selected subgroups of patients.
| Variable                          | Hypophosphatemia group | Hyperphosphatemia group |
|----------------------------------|------------------------|-------------------------|
|                                  | aOR (95% CI)           | P-value                 | aOR (95% CI) | P-value | P-value for interaction |
| Age                              |                        |                         |              |         |                          |
| Age <67 years                    | 0.74 (0.36-1.50)       | 0.40                    | 1.32 (0.80-2.20) | 0.29    | 0.69                      |
| Age >67 years                    | 0.35 (0.12-1.04)       | 0.06                    | 1.84 (1.11-1.04) | 0.02    |                          |
| Sex                              |                        |                         |              |         |                          |
| Male                             | 0.56 (0.27-1.18)       | 0.13                    | 1.79 (1.15-2.81) | 0.01    | 0.65                      |
| Female                           | 0.65 (0.25-1.68)       | 0.38                    | 1.35 (0.76-2.39) | 0.31    |                          |
| Chronic respiratory disease     |                        |                         |              |         |                          |
| Yes                              | <0.001 (<0.001- >999.9) | 0.96                  | 1.69 (0.37-7.8) | 0.50    | 0.27                      |
| No                               | 0.63 (0.35-1.13)       | 0.12                    | 1.58 (1.10-1.14) | 0.01    |                          |
| Chronic cardiac disease          |                        |                         |              |         |                          |
| Yes                              | 0.54 (0.15-1.96)       | 0.35                    | 2.23 (1.23-4.05) | 0.008   | 0.48                      |
| No                               | 0.58 (0.30-1.12)       | 0.11                    | 1.36 (0.87-2.11) | 0.18    |                          |
| Chronic renal disease            |                        |                         |              |         |                          |
| Yes                              | <0.001 (<0.001- >999.9) | 0.96                  | 1.82 (0.42-7.94) | 0.43    | 0.97                      |
| No                               | 0.63 (0.35-1.14)       | 0.13                    | 1.16 (1.11-2.30) | 0.01    |                          |
| Chronic liver disease            |                        |                         |              |         |                          |
| Yes                              | 0.39 (0.05-3.15)       | 0.37                    | 0.55 (0.13-2.25) | 0.41    | 0.007                     |
| No                               | 0.62 (0.33-1.14)       | 0.12                    | 1.68 (1.16-2.42) | 0.006   |                          |
| Chronic immunosuppression        |                        |                         |              |         |                          |
|                | Yes            | No            |        |        |
|----------------|----------------|--------------|--------|--------|
|                | 0.72 (0.27-1.94) | 0.51 (0.24-1.07) | 0.52   | 0.08   |
|                | 1.93 (0.86-4.40)  | 1.72 (1.15-2.56)  | 0.52   | 0.008  |
| **APACHE II score** |                |                |        |        |
| <23            | 0.62 (0.27-1.43)  | 0.57 (0.25-1.30)  | 0.26   | 0.18   |
|                | 1.97 (1.07-3.62)  | 1.51 (0.98-2.33)  | 0.03   | 0.06   |
| >23            |                |                |        |        |
| **Diabetes**   |                |                |        |        |
| Yes            | 0.51 (0.17-1.53)  | 0.60 (0.30-1.20)  | 0.23   | 0.15   |
|                | 1.66 (0.96-2.88)  | 1.36 (0.83-2.22)  | 0.07   | 0.22   |
| No             |                |                |        |        |
| **Vasopressors** |                |                |        |        |
| Yes            | 0.58 (0.27-1.25)  | 0.65 (0.26-1.62)  | 0.16   | 0.36   |
|                | 1.45 (0.95-2.21)  | 1.71 (0.89-3.29)  | 0.09   | 0.11   |
| No             |                |                |        |        |
| **ICU duration (days)** |                |                |        |        |
| ≤5             | 0.71 (0.26-1.95)  | 0.58 (0.27-1.23)  | 0.50   | 0.16   |
|                | 1.35 (0.70-2.60)  | 1.46 (0.92-2.30)  | 0.37   | 0.11   |
| >5             |                |                |        |        |
| **Estimated GFR** |                |                |        |        |
| ≤73 ml/min     | 0.61 (0.24-1.57)  | 0.60 (0.28-1.28)  | 0.30   | 0.18   |
|                | 1.72 (1.15-2.58)  | 1.04 (0.45-2.41)  | 0.009  | 0.93   |
| >73 ml/min     |                |                |        |        |
| **Acute Kidney Injury** |                |                |        |        |
| Yes            | 0.39 (0.07-2.14)  | 0.63 (0.34-1.17)  | 0.28   | 0.14   |
|                | 1.49 (0.79-2.82)  | 1.56 (1.02-2.40)  | 0.22   | 0.04   |
| No             |                |                |        |        |
| **Type of admission** |                |                |        |        |
| Non-operative  | 0.55 (0.30-1.00)  | 14 (0.45-434)    | 0.05   | 0.13   |
|                | 1.6 (1.10-1.14)   | 4.70 (0.22-1.14)  | 0.01   | 0.32   |
| Post-operative |                |                |        |        |
aOR: adjusted odds ratio  APACHE: Acute Physiology and Chronic Health Evaluation, CI: confidence interval, GFR: glomerular filtration rate, ICU: intensive care unit

**Table 5:** Multivariate analysis of the association of phosphate levels and hospital mortality in selected subgroups of patients.
| Variable                              | Hypophosphatemia group | Hyperphosphatemia group |
|--------------------------------------|------------------------|-------------------------|
|                                      | aOR (95% CI)           | p-value                 | aOR (95% CI)           | p-value | p-value for interaction |
| **Age (years)**                      |                        |                         |                        |         |                        |
| Age <67                               | 0.93 (0.52-1.68)       | 0.81                    | 1.60 (1.01-2.53)       | 0.05    | 0.17                    |
| Age >67                               | 0.84 (0.43-1.66)       | 0.62                    | 1.71 (1.10-2.70)       | 0.02    |                         |
| **Sex**                              |                        |                         |                        |         |                        |
| Male                                 | 0.95 (0.54-1.64)       | 0.84                    | 1.54 (1.02-2.32)       | 0.04    | 0.17                    |
| Female                               | 0.80 (0.38-1.68)       | 0.56                    | 1.87 (1.11-3.13)       | 0.02    |                         |
| **Chronic respiratory disease**      |                        |                         |                        |         |                        |
| Yes                                  | 0.48 (0.05-4.53)       | 0.52                    | 1.62 (0.40-6.49)       | 0.50    | 0.29                    |
| No                                   | 0.93 (0.59-1.46)       | 0.74                    | 1.64 (1.17-2.30)       | 0.004   |                         |
| **Chronic cardiac disease**          |                        |                         |                        |         |                        |
| Yes                                  | 1.33 (0.53-3.34)       | 0.54                    | 1.35 (0.74-2.46)       | 0.33    | 0.45                    |
| No                                   | 0.76 (0.46-1.27)       | 0.30                    | 1.68 (1.14-2.50)       | 0.01    |                         |
| **Chronic renal disease**            |                        |                         |                        |         |                        |
| Yes                                  | 0.88 (0.06-13.28)      | 0.92                    | 1.25 (0.30-5.41)       | 0.76    | 0.52                    |
| No                                   | 0.89 (0.57-1.39)       | 0.60                    | 1.70 (1.22-2.37)       | 0.002   |                         |
| **Chronic liver disease**            |                        |                         |                        |         |                        |
| Yes                                  | 0.81 (0.10-6.84)       | 0.85                    | 1.81 (0.36-9.14)       | 0.48    | 0.27                    |
| No                                   | 0.90 (0.57-1.42)       | 0.65                    | 1.54 (1.10-2.15)       | 0.01    |                         |
| **Chronic immunosuppression**        |                        |                         |                        |         |                        |
|                  | Yes               | No               | **Odds Ratio** | **95% CI**      | **P** | **OR_CI** |
|------------------|-------------------|------------------|----------------|-----------------|-------|-----------|
| APACHE II score  |                   |                  |                |                 |       |           |
| < 23             | 0.58 (0.30-1.12)  | 0.10             | 2.22 (1.32-3.74) | 0.003           | 0.05  |
| > 23             | 1.43 (0.75-0.99)  | 0.28             | 1.48 (0.99-2.22) | 0.06            |       |
| Diabetes         |                   |                  |                |                 |       |           |
| Yes              | 1.06 (0.51-2.21)  | 0.87             | 1.59 (0.97-2.58) | 0.06            | 0.38  |
| No               | 0.80 (0.46-1.40)  | 0.43             | 1.55 (0.98-2.45) | 0.06            |       |
| Vasopressors     |                   |                  |                |                 |       |           |
| Yes              | 1.11 (0.61-2.05)  | 0.73             | 1.83 (1.22-2.73) | 0.004           | 0.60  |
| No               | 0.71 (0.37-1.37)  | 0.31             | 1.27 (0.73-2.23) | 0.40            |       |
| ICU duration (days) |                |                  |                |                 |       |           |
| ≤ 5              | 0.86 (0.43-1.73)  | 0.68             | 2.29 (1.35-3.87) | 0.002           | 0.06  |
| > 5              | 0.93 (0.52-1.66)  | 0.81             | 1.31 (0.87-1.97) | 0.20            |       |
| Estimated GFR    |                   |                  |                |                 |       |           |
| ≤ 73             | 0.94 (0.44-2.03)  | 0.88             | 1.92 (1.32-2.81) | 0.0007          | 0.14  |
| >73              | 0.81 (0.47-1.40)  | 0.44             | 1.17 (0.58-2.35) | 0.67            |       |
| Acute Kidney Injury |                |                  |                |                 |       |           |
| Yes              | 0.73 (0.19-2.78)  | 0.65             | 1.74 (0.95-3.17) | 0.07            | 0.63  |
| No               | 0.91 (0.57-1.46)  | 0.71             | 1.52 (1.03-2.24) | 0.03            |       |
| Type of admission|                   |                  |                |                 |       |           |
| Non-operative    | 0.85 (0.55-1.33)  | 0.48             | 1.66 (1.20-2.30) | 0.002           | 0.70  |
| Post-operative | 6.50 (0.28-151.13) | 0.24 | 1.63 (0.12-22.98) | 0.72 |

aOR: adjusted odds ratio  
APACHE: Acute Physiology and Chronic Health Evaluation, CI: confidence interval,  
GFR: glomerular filtration rate, ICU: intensive care unit